Publicacións (28) Publicacións nas que participase algún/ha investigador/a

2020

  1. 4-1BB (CD137) in anticancer chimeras

    Journal of Experimental Medicine, Vol. 217, Núm. 12

  2. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 73, Núm. 6, pp. 1460-1469

  3. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  4. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

  5. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies

    Drug Resistance Updates, Vol. 53

  6. Cellular cytotoxicity is a form of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  7. Diverse immune environments in human lung tuberculosis granulomas assessed by quantitative multiplexed immunofluorescence

    Modern Pathology, Vol. 33, Núm. 12, pp. 2507-2519

  8. Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial

    JAMA Oncology

  9. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

    Nature Medicine, Vol. 26, Núm. 5, pp. 688-692

  10. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors

    OncoImmunology, Vol. 9, Núm. 1

  11. Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms

    Cellular and Molecular Immunology, Vol. 17, Núm. 6, pp. 576-586

  12. Exploiting TCR Recognition of Shared Hotspot Oncogene-encoded Neoantigens

    Clinical Cancer Research, Vol. 26, Núm. 6, pp. 1203-1204

  13. Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint

    Frontiers in Immunology, Vol. 11

  14. Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death

    Theranostics, Vol. 10, Núm. 10, pp. 4481-4489

  15. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma

    Blood, Vol. 136, Núm. 2, pp. 199-209

  16. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment

    Nature Immunology, Vol. 21, Núm. 2, pp. 120-134

  17. Interleukin-12 message in a bottle

    Clinical Cancer Research, Vol. 26, Núm. 23, pp. 6080-6082

  18. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

  19. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

  20. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

    ESMO open, Vol. 4, pp. e000733